Heterocyclic Compounds

Matches 1,001 - 1,050 out of 3,984	< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 >

Document	Document Title
WO/1999/066934A1	CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS Disclosed are compounds which inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
WO/1999/067220A1	COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Disclosed are compounds which inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
WO/1999/064042A1	NOVEL THERAPEUTIC AGENTS THAT MODULATE ALPHA-1A ADRENERGIC RECEPTORS Disclosed are novel multi-binding compounds (agents) which bind alpha-1A adrenergic receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological pro...
WO/1999/063996A1	MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT¿2? RECEPTORS Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the 5HT¿2? receptors, which are involved in neurological disorders. The multibinding compounds of this invention containing fr...
WO/1999/064052A1	NOVEL LEUKOTRIENE RECEPTOR ANTAGONISTS AND THEIR USES This invention relates to novel multibinding compounds that bind to leukotriene receptors and inhibit their activity. In particular, cysteinal leukotriene receptor antagonists and, most particularly leukotriene D¿4? receptor antagonist ...
WO/1999/063944A2	NOVEL THERAPEUTIC AGENTS THAT MODULATE ESTROGEN RECEPTORS Disclosed are novel multi-binding compounds (agents) which bind estrogen receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes/func...
WO/1999/064394A1	NEUROPEPTIDE Y5 RECEPTOR ANTAGONISTS Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein a and b are 0-2, provided that the sum is 0-3; Q is (i) or (-N=); X is -O-, -S-, -SO-, -SO¿2?-, -CH(OR?8¿)-, -C(O)-, -C(R?23¿)¿2?-, optionally substitute...
WO/1999/063993A1	MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE D¿1? RECEPTORS Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the D¿1? receptors, preferably, agonists of the D¿1? receptors, which are involved in neurological disorders. The multibindin...
WO/1999/063999A1	H1-HISTAMINE RECEPTOR ANTAGONISTS This invention relates to novel multibinding compounds (agents) that are H1-histamine receptor antagonists and pharmaceutical compositions comprising such compounds. Accordingly, the multibinding compounds and pharmaceutical compositions...
WO/1999/063930A2	NOVEL ANGIOTENSIN RECEPTOR MODULATORS AND THEIR USES This invention relates to novel multibinding compounds that bind to angiotensin (AT) receptors and modulate their activity. The compounds of this invention comprise 2-10 AT receptor ligands covalently connected by a linker or linkers, wh...
WO/1999/064053A1	$g(b)3-ADRENERGIC RECEPTOR AGONISTS The present invention is directed to multibinding compounds which are $g(b)3-adrenergic receptor agonists and are therefore useful in the treatment and prevention of metabolic disorders such as obesity, diabetes, and the like.
WO/1999/062879A1	UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES This invention relates to novel ureas or carbamates of N-heterocyclic carboxylic acids and carboxylic acid isosteres, their preparation and use for treating neurological disorders including physically damaged nerves and neurodegenerative...
WO/1999/062881A1	AZA-HETEROCYCLIC COMPOUNDS USED TO TREAT NEUROLOGICAL DISORDERS AND HAIR LOSS This invention relates to novel N-heterocyclic carboxylic acids and carboxylic acid isosteres represented by formula (I), their preparation and use for treating neurological disorders including physically damaged nerves and neurodegenera...
WO/1999/062880A1	N-LINKED SULFONAMIDES OF N-HETEROCYCLIC CARBOXYLIC ACIDS OR CARBOXYLIC ACID ISOSTERES This invention relates to novel N-linked sulfonamides of N-heterocyclic carboxylic acid and carboxylic acid isosteres, their preparation, and use for treating neurological disorders including physically damaged nerves and neurodegenerati...
WO/1999/061424A1	CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL Novel substituted amino acids of formulae (I) to (VIII) are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain...
WO/1999/061414A1	NOVEL SUBSTITUTED GUANIDINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME Compounds represented by general formula (1) which are useful as remedies and preventives for diseases caused by acceleration in the sodium/proton exchange system, wherein R¿1?, R¿2?, R¿3?, R¿4? and R¿5? represent each hydrogen, alk...
WO/1999/059959A1	BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES The invention concerns amide derivatives of Formula (I), wherein R?3¿ is (1-6C)alkyl or halogeno; m is 1-3 and R?1¿ is selected from substituents such as: (A) hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, aryl, heteroaryl and heterocyc...
WO/1999/058501A1	COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES The present invention relates to novel compounds, in particular 4,4-disubstituted and 3,3-disubstituted piperidine compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growt...
WO/1999/055690A1	GUANIDINE DERIVATIVES This invention relates to guanidine derivatives of formula (I) wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising...
WO/1999/055355A1	AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula (I) wherein X is O or NR?19¿ and A?1¿, A?2¿, R?7¿-R?10¿, R?18¿, R?a¿, R?b¿, R?c¿, n and m are set forth in the spe...
WO/1999/054321A1	SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS The invention is directed to physiologically active compounds of general formula (I): wherein R?1¿ represents R?5¿-L?3¿-, R?5¿-L?4¿-R?6¿-, R?5¿-L?4¿-R?7¿-L?5¿-, R?5¿-L?4¿-Ar?1¿-L?3¿-, R?5¿-L?4¿-Ar?1¿-L?6¿-R?6¿- or R?5�...
WO/1999/052877A1	RECEPTOR LIGANDS Non-antibody multimeric receptor ligands, methods for making and identifying them and their use for agonizing or antagonizing multimeric receptors.
WO/1999/052879A1	ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS Compounds of formula (I) are useful in the treatment of various disorders including, but not limited to, cancer, angiogenesis, restenosis, inflammation, bone diseases, and as antiviral agents. Novel methods of makings compounds of formul...
WO/1999/052865A1	PURIFICATION OF CAPROLACTAM FROM RECYCLED NYLON A method of removing 1,11-diamino-6-undecanone from the pyrolysis product of nylon comprising: a) pyrolyzing nylon-6 to form a pyrolyzate containing a caprolactam mixture; b) dissolving the caprolactam mixture in a solvent to form a solu...
WO/1999/051571A1	BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula (I), wherein X is O or NH, L is -O- or -SO¿2?-, and R?1¿-R?4¿, R?9¿-R?19¿, R?a¿, R?b¿, R?c¿, Y, Z, n and m are set ...
WO/1999/048491A1	NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE NF-$g(k)B inhibitors containing as the active ingredient benzoquinone derivatives represented by general formula (I), hydroquinone compounds thereof or salts of the same, wherein R¿1?, R¿2? and R¿3? independently represent each H, C¿...
WO/1999/048872A2	METHOD FOR SEPARATING AN AZEPINE DERIVATIVE FROM A MIXTURE CONTAINING AN AMINE AND AN AZEPINE DERIVATIVE The invention relates to a method for separating by distillation all or part of an azepine derivative (III) selected from the group consisting of amino hexylidenimine, tetrahydroazepine, hexylhexahydroazepine and amino hexylhexahydroazep...
WO/1999/043670A1	BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D¿4? RECEPTOR ANTAGONISTS Disclosed are compounds of formula (I) or pharmaceutically acceptable addition salts thereof wherein: Y represents oxygen or sulfur; Z is nitrogen or CH; R¿1?, R¿2? and R¿3? represents hydrogen, halogen, hydroxy, alkoxy, alkyl, triflu...
WO/1999/042436A1	N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes inc...
WO/1999/037619A1	CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by s...
WO/1999/036403A1	NOVEL DOPAMINE RE-UPTAKE INHIBITORS AND METHODS OF SYNTHESIZING AND USING THE SAME The invention comprises dopamine re-uptake inhibitors, and methods of making and using such inhibitors. The inhibitors include methylphenidate, $i(threo-)methylphenidate, and analogs thereof.
WO/1999/035145A1	DEPROTECTION AND RECRYSTALLIZATION PROCESSES Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions by including an agent which minimizes the amount of disulfides. Suitable agents are bis...
WO/1999/033789A1	SUBSTITUTED $g(b)-ALANINES The invention is directed to physiologically active compounds of general formula (I), wherein R?1¿ is hydrogen, halogen, lower alkyl or lower alkoxy; X?1¿, X?2¿ and X?6¿ independently represent N or CR?2¿; and one of X?3¿, X?4¿ an...
WO1999025686B1	CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUGS A compound represented by general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. Since these compounds inhibit the...
WO/1999/032452A1	CARBOXYL ACID SUBSTITUTED HETEROCYCLES AS METALLOPROTEINASE INHIBITORS The present invention relates to metalloproteinase inhibitors of formula (I) or a pharmaceutically acceptable salt thereof for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases. The inve...
WO/1999/032468A1	ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF This invention is provide a compound of formula (I) wherein R?1¿ is an optionally substituted 5- to 6-membered ring; W is a divalent group of formula (a) or (b) wherein the ring A is an optionally substituted 5- to 6-membered aromatic r...
WO/1999/032453A1	POLYCYCLIC $g(a)-AMINO-$m(e)-CAPROLACTAMS AND RELATED COMPOUNDS Disclosed are polycyclic $g(a)-amino-$m(e)-caprolactams and related compounds which are useful as synthetic intermediates in the preparation of inhibitors of $g(b)-amyloid peptide release and/or its synthesis.
WO/1999/032451A1	AZEPINE OR LARGER MEDIUM RING DERIVATIVES AND THEIR USE AS PHARMACEUTICALS Selected novel azepine and larger medium ring compounds are effective for prophylaxis and treatment of inflammation, tissue degradation and related diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutical...
WO/1999/026928A1	SYNTHESIS OF 11-ARYL-5,6-DIHYDRO-11H-DIBENZ[B,E]AZEPINES Disclosed in a three step synthesis of 11-aryl-5,6-dihydro-11H-dibenz[b,e]azepines from a 2-aminobenzophenone represented by structural formula (II) and a starting material represented by structural formula (III). Phenyl Ring A, Phenyl R...
WO/1999/026929A1	SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation $i(in situ) as...
WO/1999/026628A1	USE OF SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHEA AND SCOUR The present invention provides substituted 11-phenyl-dibenzazepine compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of the Ca?2+¿-activated potassium channel (Gardos channel) of erythrocytes, of ma...
WO/1999/021836A1	SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS Novel compounds of formula (I) are useful in the prophylaxis and treatment of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated wit...
WO/1999/020599A1	PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE The present invention relates to pharmaceutically acceptable compounds, including acylguanidine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the inv...
WO/1999/018966A1	PARENTERAL FORMULATIONS COMPRISING CARBAMAZEPINE OR ITS DERIVATIVES The invention is concerned with a parenteral formulation comprising a 5H-dibenz(b,f)azepine-5-carboxamide and an aqueous-based solvent. The parenteral formulation is useful in the treatment of seizures resulting from, e.g. epileptic attack.
WO/1999/020081A2	HIGHLY TRANSPARENT NON-METALLIC CATHODES A novel class of low reflectivity, high transparency, non-metallic cathodes (1) useful for a wide range of electrically active, transparent organic devices is disclosed. As a representative embodiment, the highly transparent non-metallic...
WO/1999/014998A2	METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering sensorineurotrophic compounds described below. The invention rel...
WO/1999/015178A1	VITRONECTIN RECEPTOR ANTAGONIST A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis, or a pharmaceutically acceptable salt thereof.
WO/1999/011626A1	INTEGRIN RECEPTOR ANTAGONISTS This invention relates to the seven membered at least one nitrogen containing tricyclic heterocyclic pharmaceutically active compounds which bind to integrins, such as the vitronectin receptor and fibrinogen receptor. Such compounds are ...
WO/1999/011614A1	CAPROLACTAM PRODUCTION PROCESS The invention relates to a process for producing cyclic lactams by reacting aminocarboxylic acid nitriles with water, in liquid phase, in a fixed bed reactor, in the presence of a catalyst containing a catalytically active oxide comprisi...
WO/1999/009991A1	NOVEL AMIDE DERIVATIVES Disclosed are the novel compounds represented by structural Formula (I), wherein A is a lipophilic group comprising an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group a...

Matches 1,001 - 1,050 out of 3,984	< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 >